After six months, DYNE-251 recipients reached higher levels of dystrophin than patients in a separate study of Sarepta's Exondys 51. Dyne stock, which has already more than doubled this year ...

In this article, we are going to take a look at where Dyne Therapeutics ... aligning rates toward neutral levels. Contrastingly, Goldman Sachs offers a more optimistic outlook, forecasting ...

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dyne Therapeutics with a $49.17 average price target, a 295.9% upside from current levels. In a report issued on ...